ASCO 2018: More Lung Cancer Patients Could Benefit From Immunotherapy Over Chemo – R & D Magazine
R & D Magazine |
ASCO 2018: More Lung Cancer Patients Could Benefit From Immunotherapy Over Chemo
R & D Magazine A new study demonstrates that immunotherapeutic agent pembrolizumab (Keytruda) is more effective than chemotherapy as a first-line treatment for most patients with a common type of lung cancer, regardless of patients’ expression of PD-L1, a protein … |
|
A change in bacteria’s genetic code holds promise of longer-lasting drugs
Science Daily “We have been able to expand the genetic code to make new, biomedically relevant proteins,” said Andrew Ellington, associate director of the Center for Systems and Synthetic Biology and a professor of molecular biosciences who co-authored the study. |
|
A change in bacteria’s genetic code holds promise of longer-lasting drugs
Science Daily “We have been able to expand the genetic code to make new, biomedically relevant proteins,” said Andrew Ellington, associate director of the Center for Systems and Synthetic Biology and a professor of molecular biosciences who co-authored the study. |